Cross-reactivity, epitope spreading, and de novo immune stimulation are possible mechanisms of cross-protection of nonvaccine human papillomavirus (HPV) types in recipients of HPV therapeutic vaccines

Clinical and Vaccine Immunology

Volumn 22, Issue 7, 2015, Pages 679-687

  Nakagawa, Mayumi ^a   Greenfield, William ^a   Moerman Herzog, Andrea ^a   Coleman, Hannah N ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMID DNA; WART VIRUS VACCINE; EPITOPE;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGENICITY; BIODEGRADABILITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL SPREADING; CELLULAR IMMUNITY; CROSS REACTION; DRUG EFFICACY; DRUG SAFETY; EPITOPE MAPPING; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOSTIMULATION; PAPILLOMAVIRUS INFECTION; PHYLOGENY; PRIORITY JOURNAL; PROTEIN PURIFICATION; REVIEW; SEQUENCE HOMOLOGY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LIKE AGENT; VIRUS STRAIN; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPLICATION; CROSS PROTECTION; IMMUNOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; TREATMENT OUTCOME; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CROSS PROTECTION; EPITOPES; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME;

EID: 84936886059     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00149-15     Document Type: Review

References (71)

1. American Cancer Society. 2014. Cancer Facts & Figures 2014. American Cancer Society, Atlanta, Georgia.
2. Chaturvedi AK. 2010. Beyond cervical cancer: burden of other HPVrelated cancers among men and women. J Adolesc Health 46(Suppl):S20-S26. http://dx.doi.org/10.1016/j.jadohealth.2010.01.016.
3. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. 2011. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med 53(Suppl 1):S12-S21. http://dx.doi.org/10.1016/j.ypmed.2011.08.017.
4. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Schymura MJ, Anderson RN, Yankey D, Edwards BK. 2013. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 105:175-201. http://dx.doi.org/10.1093/jnci/djs491.
5. Van Regenmortel MHV, Fauquet CM, Bishop DHL, Calisher CH, Carsten EB, Estes MK, Lemon SM, Maniloff J, Mayo MA, McGeoch DJ, Pringle CR, Wickner RB. 2002. Virus taxonomy. Seventh report of the International Committee for the Taxonomy of Viruses. Academic Press, New York, NY.
6. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70-79. http://dx.doi.org/10.1016/j.virol.2010.02.002.
7. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E. 2009. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199:926-935. http://dx.doi.org/10.1086/597307.
8. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-1255. http://dx.doi.org/10.1016/S0140-6736(06)68439-0.
9. Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M. 2014. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV-16/18 and closely related HPV types. Br J Cancer 110:2804-2811. http://dx.doi.org/10.1038/bjc.2014.198.
10. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. 2012. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:781-789. http://dx.doi.org/10.1016/S1473-3099(12)70187-1.
11. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314. http://dx.doi.org/10.1016/S0140-6736(09)61248-4.
12. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E. 2009. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 199:936-944. http://dx.doi.org/10.1086/597309.
13. Szarewski A. 2007. Prophylactic HPV vaccines. Eur J Gynaecol Oncol 28:165-169.
14. Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ. 2013. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infect Dis 13:75. http://dx.doi.org/10.1186/1471-2334-13-75.
15. Draper E, Bissett SL, Howell-Jones R, Edwards D, Munslow G, Soldan K, Beddows S. 2011. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 29:8585-8590. http://dx.doi.org/10.1016/j.vaccine.2011.09.021.
16. Bissett SL, Draper E, Myers RE, Godi A, Beddows S. 2014. Crossneutralizing antibodies elicited by the Cervarix(R) human papillomavirus vaccine display a range of alpha-9 inter-type specificities. Vaccine 32: 1139-1146. http://dx.doi.org/10.1016/j.vaccine.2014.01.008.
17. Scherpenisse M, Schepp RM, Mollers M, Meijer CJ, Berbers GA, van der Klis FR. 2013. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One 8:e74797. http://dx.doi.org/10.1371/journal.pone.0074797.
18. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, Inglis SC. 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523-1527. http://dx.doi.org/10.1016/S0140-6736(96)90674-1.
19. Brun JL, Dalstein V, Leveque J, Mathevet P, Raulic P, Baldauf JJ, Scholl S, Huynh B, Douvier S, Riethmuller D, Clavel C, Birembaut P, Calenda V, Baudin M, Bory JP. 2011. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 204:169.e1-8. http://dx.doi.org/10.1016/j.ajog.2010.09.020.
20. Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC. 2010. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 102:1129-1136. http://dx.doi.org/10.1038/sj.bjc.6605611.
21. Davidson EJ, Faulkner RL, Sehr P, Pawlita M, Smyth LJ, Burt DJ, Tomlinson AE, Hickling J, Kitchener HC, Stern PL. 2004. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 22:2722-2729. http://dx.doi.org/10.1016/j.vaccine.2004.01.049.
22. Frazer IH, Quinn M, Nicklin JL, Tan J, Perrin LC, Ng P, O?Connor VM, White O, Wendt N, Martin J, Crowley JM, Edwards SJ, McKenzie AW, Mitchell SV, Maher DW, Pearse MJ, Basser RL. 2004. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23:172-181. http://dx.doi.org/10.1016/j.vaccine.2004.05.013.
23. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361:1838 -1847. http://dx.doi.org/10.1056/NEJMoa0810097.
24. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M, Palefsky JM. 2002. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res 8:1028-1037.
25. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J. 2000. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6:3406-3416.
26. Sheets EE, Urban RG, Crum CP, Hedley ML, Politch JA, Gold MA, Muderspach LI, Cole GA, Crowley-Nowick PA. 2003. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 188:916-926. http://dx.doi.org/10.1067/mob.2003.256.
27. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. 2009. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 15:361-367. http://dx.doi.org/10.1158/1078-0432.CCR-08-1725.
28. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, Contreras ML, Padilla S, Guzman CC, Jimenez R, Reyes L, Morosoli G, Verde ML, Rosales R. 2006. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 13:592-597. http://dx.doi.org/10.1038/sj.cgt.7700937.
29. Santin AD, Bellone S, Palmieri M, Bossini B, Roman JJ, Cannon MJ, Bignotti E, Cane S, Pecorelli S. 2003. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol 89:271-280. http://dx.doi.org/10.1016/S0090-8258(03)00083-0.
30. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ. 2008. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 82:1968-1979. http://dx.doi.org/10.1128/JVI.02343-07.
31. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML, Beach KJ. 2004. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 103:317-326. http://dx.doi.org/10.1097/01.AOG.0000110246.93627.17.
32. Nieminen P, Harper DM, Einstein MH, Garcia F, Donders G, Huh W, Wright TC, Stoler M, Ferenczy A, Rutman O, Shikhman A, Leung M, Clinch B, Calleja E. 2012. Efficacy and safety of RO5217990 treatment in patients with high grade cervical intraepithelial neoplasia (CIN2/3), p 206. 28th Int Papillomavirus Conf Abstr Book Clin Sci. 28th IPV Conference, San Juan, Puerto Rico, 30 November to 6 December 2012.
33. Greenfield WW, Stratton S, Myrick R, Vaughn R, Donnalley L, Coleman H, Mercado M, Moerman-Herzog A, Spencer H, Andrews-Collins N, Hitt W, Low G, Manning N, McKelvey S, Smith D, Smith M, Phillips A, Quick C, Jeffus S, Hutcins L, Nakagawa M. A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. Oncoimmunology, in press.
34. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. 2004. Classification of papillomaviruses. Virology 324:17-27. http://dx.doi.org/10.1016/j.virol.2004.03.033.
35. Kim KH, Dishongh R, Santin AD, Cannon MJ, Bellone S, Nakagawa M. 2006. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. Cancer Immun 6:9.
36. Wang X, Greenfield WW, Coleman HN, James LE, Nakagawa M. 2012. Use of interferon-gamma enzyme-linked immunospot assay to character-ize novel T-cell epitopes of human papillomavirus. J Vis Exp 2012:3657. http://dx.doi.org/10.3791/3657.
37. Wang X, Moscicki AB, Tsang L, Brockman A, Nakagawa M. 2008. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. Clin Vaccine Immunol 15:937-945. http://dx.doi.org/10.1128/CVI.00404-07.
38. Coleman HA, Wang X, Greenfield WW, Nakagawa M. 2014. A human papillomavirus type 16 E6 52-62 CD4 T-cell epitope restricted by the HLA-DR11 molecule described in an epitope hotspot. MOJ Immunology 1:00018. http://dx.doi.org/10.15406/moji.2014.01.00018.
39. van den Hende M, Redeker A, Kwappenberg KM, Franken KL, Drijfhout JW, Oostendorp J, Valentijn AR, Fathers LM, Welters MJ, Melief CJ, Kenter GG, van der Burg SH, Offringa R. 2010. Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-specific CD4+ memory T cell responses. J Infect Dis 202:1200-1211. http://dx.doi.org/10.1086/656367.
40. Ribas A, Timmerman JM, Butterfield LH, Economou JS. 2003. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 24:58-61. http://dx.doi.org/10.1016/S1471 -4906(02)00029-7.
41. Getts DR, Chastain EM, Terry RL, Miller SD. 2013. Virus infection, antiviral immunity, and autoimmunity. Immunol Rev 255:197-209. http://dx.doi.org/10.1111/imr.12091.
42. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. 2000. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102-3108.
43. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS. 2003. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998-1008.
44. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH. 2001. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243-251. http://dx.doi.org/10.1002/ijc.1323.
45. Lally KM, Mocellin S, Ohnmacht GA, Nielsen MB, Bettinotti M, Panelli MC, Monsurro V, Marincola FM. 2001. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int J Cancer 93:841-847. http://dx.doi.org/10.1002/ijc.1420.
46. Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T, Storkus WJ. 2000. Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest 29:121-125. http://dx.doi.org/10.3109/08820130009062294.
47. Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G. 2012. Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 1:670-686. http://dx.doi.org/10.4161/onci.20426.
48. Clifton MM, Johnson SM, Roberson PK, Kincannon J, Horn TD. 2003. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol 20:268-271. http://dx.doi.org/10.1046/j.1525-1470.2003.20318.x.
49. Horn TD, Johnson SM, Helm RM, Roberson PK. 2005. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol 141:589 -594. http://dx.doi.org/10.1001/archderm.141.5.589.
50. Johnson SM, Horn TD. 2004. Intralesional immunotherapy for warts using a combination of skin test antigens: a safe and effective therapy. J Drugs Dermatol 3:263-265.
51. Johnson SM, Roberson PK, Horn TD. 2001. Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol 137:451-455.
52. Kim KH, Horn TD, Pharis J, Kincannon J, Jones R, O?Bryan K, Myers J, Nakagawa M. 2010. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol 146:1431-1433. http://dx.doi.org/10.1001/archdermatol.2010.350.
53. Maronn M, Salm C, Lyon V, Galbraith S. 2008. One-year experience with candida antigen immunotherapy for warts and molluscum. Pediatr Dermatol 25:189-192. http://dx.doi.org/10.1111/j.1525-1470.2008.00630.x.
54. Phillips RC, Ruhl TS, Pfenninger JL, Garber MR. 2000. Treatment of warts with Candida antigen injection. Arch Dermatol 136:1274-1275. http://dx.doi.org/10.1001/archderm.136.10.1274.
55. Esch RE, Buckley CE, III. 1988. A novel Candida albicans skin test antigen: efficacy and safety in man. J Biol Stand 16:33-43. http://dx.doi.org/10.1016/0092-1157(88)90027-3.
56. Nakagawa M, Coleman HN, Wang X, Daniels J, Sikes J, Nagarajan UM. 2014. IL-12 secretion by Langerhans cells stimulated with Candida skin test reagent is mediated by dectin-1 in some healthy individuals. Cytokine 65:202-209. http://dx.doi.org/10.1016/j.cyto.2013.11.002.
57. Wang X, Coleman HN, Nagarajan U, Spencer HJ, Nakagawa M. 2013. Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine. Vaccine 31:5806-5813. http://dx.doi.org/10.1016/j.vaccine.2013.10.014.
58. Eassa BI, Abou-Bakr AA, El-Khalawany MA. 2011. Intradermal injection of PPD as a novel approach of immunotherapy in anogenital warts in pregnant women. Dermatol Ther 24:137-143. http://dx.doi.org/10.1111/j.1529-8019.2010.01388.x.
59. Piersma SJ, Welters MJ, van der Hulst JM, Kloth JN, Kwappenberg KM, Trimbos BJ, Melief CJ, Hellebrekers BW, Fleuren GJ, Kenter GG, Offringa R, van der Burg SH. 2008. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 122:486-494. http://dx.doi.org/10.1002/ijc.23162.
60. Gallagher KM, Man S. 2007. Identification of HLA-DR1- and HLADR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women. J Gen Virol 88:1470-1478. http://dx.doi.org/10.1099/vir.0.82558-0.
61. van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ, Offringa R. 2001. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 91:612-618. http://dx.doi.org/10.1002/1097-0215(200002)9999 :9999-::AID-IJC11193.0.CO;2-C.
62. Wang X, Santin AD, Bellone S, Gupta S, Nakagawa M. 2009. A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. Cancer Immunol Immunother 58:301-308. http://dx.doi.org/10.1007/s00262 -008-0525-2.
63. Okubo M, Saito M, Inoku H, Hirata R, Yanagisawa M, Takeda S, Kinoshita K, Maeda H. 2004. Analysis of HLA-DRB1∗0901-binding HPV-16 E7 helper T cell epitope. J Obstet Gynaecol Res 30:120-129. http://dx.doi.org/10.1111/j.1447-0756.2003.00171.x.
64. Peng S, Trimble C, Wu L, Pardoll D, Roden R, Hung CF, Wu TC. 2007. HLA-DQB1∗02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated highgrade squamous intraepithelial lesions. Clin Cancer Res 13:2479-2487. http://dx.doi.org/10.1158/1078-0432.CCR-06-2916.
65. Nakagawa M, Kim KH, Gillam TM, Moscicki AB. 2007. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol 81:1412-1423. http://dx.doi.org/10.1128/JVI.01768-06.
66. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM. 1995. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A∗0201-binding peptides. J Immunol 154:5934-5943.
67. Nakagawa M, Kim KH, Moscicki AB. 2004. Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins. Clin Diagn Lab Immunol 11:889-896. http://dx.doi.org/10.1128/CDLI.11.5.889-896.2004.
68. Bourgault Villada I, Beneton N, Bony C, Connan F, Monsonego J, Bianchi A, Saiag P, Levy JP, Guillet JG, Choppin J. 2000. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. Eur J Immunol 30:2281-2289. http://dx.doi.org/10.1002/1521 -4141(2000)30:8-2281::AID-IMMU22813.0.CO;2-N.
69. Oerke S, Hohn H, Zehbe I, Pilch H, Schicketanz KH, Hitzler WE, Neukirch C, Freitag K, Maeurer MJ. 2005. Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer. Int J Cancer 114:766-778. http://dx.doi.org/10.1002/ijc.20794.
70. Keskin DB, Reinhold B, Lee SY, Zhang G, Lank S, O?Connor DH, Berkowitz RS, Brusic V, Kim SJ, Reinherz EL. 2011. Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens. Front Immunol 2:75. http://dx.doi.org/10.3389/fimmu.2011.00075.
71. Jang S, Kim YT, Chung HW, Lee KR, Lim JB, Lee K. 2012. Identification of novel immunogenic human leukocyte antigen-A 2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer. Cancer 118:2173-2183. http://dx.doi.org/10.1002/cncr.26468.